Disclosure title: Cloning and Characterization A Murine and Human Gene with Homology to the IL-17 Receptor Application: Cancer diagnostics/therapies and general medical treatments that rely on immune system modulation (Leukemia and Immunology). IL mediated synergistic enhancement of signaling. This discovery describes the genetic cloning and sequencing of a novel IL-17 receptor-related gene in human and mouse. The expression of this gene is upregulated by viral integration in murine acute myeloid leukemia. Both the mouse and human full-length cDNA sequences have been cloned. Since this receptor is part of the interleukin family, the ligand that binds to this receptor is a cytokine. Based on the gene's proposed involvement in leukemia development, the discovery can be used as a research tool in basic research in cell growth and differentiation. Additionally, as putative cytokine receptor this gene will be useful in basic immunology studies. Any therapeutic that provokes an immuno modulatory response can take advantage of the expression properties of this IL receptor signaling target. This discovery should be particularly useful in cancer diagnostics and therapies. This novel gene may have additional roles that facilitate myeloid cell transformation, modulate the immune system, and be involved in human disease.
U.S. Patent #7,094,886
U.S. Patent Application #11/128,403
US-2005-0208572-A1 published 9/22/05
References:Oncogene (2000) 19, 2098 – 2109 “Evi27 encodes a novel membrane protein with homology to the IL17 receptor”
Seeking a Licensing Partner to commercialize this technology.
Licensing Status: Available for Exclusive Licensing
Mr. Christopher Fasel
Associate Director or Licensing
UAMS BioVentures - TLO
Medical School - Teaching Hospital - Research InstitutionView profile
Clients in focus...